milrinone

Summary

Summary: A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the ionotropic potency of amrinone.

Top Publications

  1. ncbi Intravenous milrinone in cardiac surgery
    Jerrold H Levy
    Division of Cardiothoracic Anesthesiology and Critical Care, Emory University School of Medicine and Emory Healthcare, Atlanta, Georgia, USA
    Ann Thorac Surg 73:325-30. 2002
  2. ncbi Case studies in heart failure
    Sara Paul
    Hickory Cardiology Associates, 1771 Tate Blvd SE, Suite 201, Hickory, NC 28602, USA
    Crit Care Nurs Clin North Am 15:519-23, x. 2003
  3. ncbi Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants
    Mary Paradisis
    Department of Neonatal Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    J Pediatr 154:189-95. 2009
  4. ncbi Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circ Heart Fail 1:25-33. 2008
  5. ncbi Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone
    Damien Barraud
    Equipe d Accueil 322, Universite, Paris, France
    Crit Care Med 35:1376-82. 2007
  6. ncbi Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery
    Gregory A Fleming
    Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Circulation 118:1619-25. 2008
  7. ncbi Anti-ischemic effects of inotropic agents in experimental right ventricular infarction
    M Hein
    Department of Anesthesiology, University Hospital of Aachen, Aachen, Germany
    Acta Anaesthesiol Scand 53:941-8. 2009
  8. ncbi Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase
    S Sanada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
    Circulation 104:705-10. 2001
  9. ncbi Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery
    Emad Al-Shawaf
    Department of Anesthesia, The Chest Diseases Hospital, Ministry of Health, Safat, Kuwait
    J Cardiothorac Vasc Anesth 20:353-7. 2006
  10. ncbi Differential effects of amrinone and milrinone upon myocardial inflammatory signaling
    Nikhil K Chanani
    Department of Anesthesia, Children's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 106:I284-9. 2002

Research Grants

  1. MYOCARDIAL ENERGY METABOLISM IN THE DYSFUNCTIONAL LV
    Jianyi Zhang; Fiscal Year: 2003
  2. EFFECTS OF HORMONES ON BONE RESORPTION IN VITRO
    Paula Stern; Fiscal Year: 1992
  3. Potentiation of Ang II-Induced Renal Vasoconstriction
    Edwin Jackson; Fiscal Year: 2006
  4. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
  5. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2007
  6. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2009
  7. Potentiation of Ang II Induced Renal Vasoconstriction
    Edwin Jackson; Fiscal Year: 2007
  8. Regulation of Renal Cortical Adenosine Levels
    Edwin K Jackson; Fiscal Year: 2010
  9. Potentiation of Ang II Induced Renal Vasoconstriction
    Edwin K Jackson; Fiscal Year: 2010
  10. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2009

Detail Information

Publications194 found, 100 shown here

  1. ncbi Intravenous milrinone in cardiac surgery
    Jerrold H Levy
    Division of Cardiothoracic Anesthesiology and Critical Care, Emory University School of Medicine and Emory Healthcare, Atlanta, Georgia, USA
    Ann Thorac Surg 73:325-30. 2002
    Phosphodiesterase inhibitors including milrinone produce positive inotropic effects by slowing the hydrolysis of cyclic adenosine monophosphate in the myocardium. With a loading dose of 50 microg/kg followed by an infusion of 0...
  2. ncbi Case studies in heart failure
    Sara Paul
    Hickory Cardiology Associates, 1771 Tate Blvd SE, Suite 201, Hickory, NC 28602, USA
    Crit Care Nurs Clin North Am 15:519-23, x. 2003
    ..This article presents four case studies of patients with heart failure and the rationale for optimal treatment in each case...
  3. ncbi Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants
    Mary Paradisis
    Department of Neonatal Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia
    J Pediatr 154:189-95. 2009
    To assess the effectiveness of early prophylactic milrinone versus placebo for prevention of low systemic blood flow in high-risk preterm infants.
  4. ncbi Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circ Heart Fail 1:25-33. 2008
    ..Less is known about the changes and relationships among these variables and the postdischarge survival rate...
  5. ncbi Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone
    Damien Barraud
    Equipe d Accueil 322, Universite, Paris, France
    Crit Care Med 35:1376-82. 2007
    ..Our study aimed to fully characterize both systolic and diastolic abnormalities of sepsis-associated heart failure and to identify treatment that would support full-cycle cardiac improvement...
  6. ncbi Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery
    Gregory A Fleming
    Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Circulation 118:1619-25. 2008
    ..Inotropic drugs are commonly used perioperatively to support ventricular function. This study tested the hypothesis that the use of inotropic drugs is associated with postoperative AF...
  7. ncbi Anti-ischemic effects of inotropic agents in experimental right ventricular infarction
    M Hein
    Department of Anesthesiology, University Hospital of Aachen, Aachen, Germany
    Acta Anaesthesiol Scand 53:941-8. 2009
    ..Therefore, we used a porcine model of RV ischemia and reperfusion (IR) injury to study the influence of milrinone, levosimendan and dobutamine on the extent and degree of myocardial injury.
  8. ncbi Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase
    S Sanada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
    Circulation 104:705-10. 2001
    ..Methods and Results-- Milrinone, olprinone (PDEIII-Is), or dibutyryl-cAMP (db-cAMP) was injected intravenously 30 minutes before 90-minute ..
  9. ncbi Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery
    Emad Al-Shawaf
    Department of Anesthesia, The Chest Diseases Hospital, Ministry of Health, Safat, Kuwait
    J Cardiothorac Vasc Anesth 20:353-7. 2006
    ..in 2 groups of type 2 diabetic patients with depressed myocardial function who underwent elective surgery for coronary artery disease and who received levosimendan or milrinone for postcardiopulmonary bypass low-output syndrome.
  10. ncbi Differential effects of amrinone and milrinone upon myocardial inflammatory signaling
    Nikhil K Chanani
    Department of Anesthesia, Children's Hospital and Harvard Medical School, Boston, Mass 02115, USA
    Circulation 106:I284-9. 2002
    ..We therefore examined the effects of 2 commonly used PDEIs, amrinone and milrinone, on cardiac cell inflammatory responses...
  11. ncbi Intestinal hemodynamic effects of milrinone in asphyxiated newborn pigs after reoxygenation with 100% oxygen: a dose-response study
    Chloe Joynt
    Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
    Shock 31:292-9. 2009
    Neonatal asphyxia can result in poor perfusion, vasoconstriction, and decreased oxygen delivery in the intestine. Milrinone increases myocardial contractility and causes peripheral vasodilatation...
  12. ncbi Milrinone facilitates resuscitation from cardiac arrest and attenuates postresuscitation myocardial dysfunction
    James T Niemann
    Harbor UCLA Medical Center, Department of Emergency Medicine and the David Geffen UCLA School of Medicine, Los Angeles, Calif, USA
    Circulation 108:3031-5. 2003
    ..The purpose of this study was to investigate the use of milrinone, a selective phosphodiesterase III inhibitor, as treatment for LV dysfunction after resuscitation.
  13. ncbi Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion
    Ming He Huang
    Department of Internal Medicine, Cardiology Division M HH, YW, VN, SR, BFU, KF, University of Texas Medical Branch, Galveston, TX, USA
    Cardiovasc Drugs Ther 25:223-32. 2011
    The present study determined whether late-ischemia/early reperfusion therapy with the β(1)-adrenergic receptor (AR) blocker esmolol and phosphodiesterase III inhibitor milrinone reduced left ventricular (LV) myocardial infarct size (IS).
  14. ncbi Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart
    Yasmin Shakur
    Otsuka Maryland Research Institute, 9900 Medical Center Drive, Rockville, MD 20850, USA
    Cardiovasc Drugs Ther 16:417-27. 2002
    We investigated the basis for the difference in the cardiotonic effects of the PDE3 inhibitors cilostazol and milrinone in the rabbit heart...
  15. ncbi Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts
    Shuhei Matsumoto
    Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan
    Cardiovasc Diabetol 11:4. 2012
    The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (..
  16. ncbi Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone
    Mitsuhisa Nishiguchi
    Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Okayama, Japan
    Neurosurgery 66:158-64; discussion 164. 2010
    Cerebral vasospasm remains a major cause of morbidity and mortality. Milrinone, a bipyridine phosphodiesterase III inhibitor, is a potent member of the inodilator class of cardiac agents for vasospasm and is injected intra-arterially or ..
  17. ncbi Effect of milrinone on short-term outcome of patients with myocardial dysfunction undergoing coronary artery bypass graft: A randomized controlled trial
    Mohammad Jebeli
    Cardiac Surgery Department, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran
    Cardiol J 17:73-8. 2010
    ..In this study, we evaluate the effect of milrinone on patients with ventricular dysfunction undergoing coronary artery bypass graft (CABG).
  18. ncbi Effect of milrinone on left ventricular relaxation and Ca(2+) uptake function of cardiac sarcoplasmic reticulum
    M Yano
    Second Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi 755 8505, Japan
    Am J Physiol Heart Circ Physiol 279:H1898-905. 2000
    b>Milrinone, a phosphodiesterase 3 (PDE3) inhibitor, is known to enhance left ventricular (LV) contractility by an inhibition of the breakdown of cAMP through the mechanism inhibiting PDE3...
  19. ncbi Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema
    Shih Min Wang
    Department of Emergency Medicine, College of Medicine, National Cheng Kung University and Hospital, Tainan, Taiwan
    Pediatr Pulmonol 39:219-23. 2005
    ..This study was designed to evaluate the potential therapeutic effect of milrinone, a phosphodiesterase (PDE) inhibitor, in the treatment of patients with EV71-induced pulmonary edema...
  20. ncbi Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery
    Pierre Couture
    Department of Anesthesiology, Montreal Heart Institute, Montreal, Quebec, Canada
    Can J Anaesth 54:509-22. 2007
    To evaluate the effect of milrinone on diastolic function during coronary artery bypass grafting surgery (CABG).
  21. ncbi New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase
    M Floreani
    Dipartimento di Farmacologia e Anestesiologia, Sezione di Farmacologia, , 35131, Padova, Italy
    Naunyn Schmiedebergs Arch Pharmacol 367:109-18. 2003
    Two mechanisms are responsible for the positive inotropic effect of the cardiotonic drug milrinone, i.e., inhibition of type III cAMP phosphodiesterase (PDE III), and displacement of endogenous adenosine from A(1) inhibitory receptor...
  22. ncbi Slow induction of milrinone after coronary artery bypass grafting
    T Shibata
    Division of Cardiovascular Surgery, Second Department of Surgery, Osaka City University Medical School, 1-4-3 Asahi-machi, Abeno, Osaka 545-8585, Japan
    Ann Thorac Cardiovasc Surg 7:23-7. 2001
    The aim of this study was to evaluate the hemodynamic effects of a slow induction of milrinone after open heart surgery...
  23. ncbi Effects of milrinone versus epinephrine on left ventricular relaxation after cardiopulmonary bypass following myocardial revascularization: assessment by color m-mode and tissue Doppler
    Emilio B Lobato
    Department of Anesthesiology, University of Florida College of Medicine and Veterans Affairs Medical Center, Gainesville, 32610, USA
    J Cardiothorac Vasc Anesth 19:334-9. 2005
    The purpose of this study was to evaluate the left ventricular lusitropic effects of epinephrine versus milrinone after cardiopulmonary bypass.
  24. ncbi Efficacy of pre-emptive milrinone in off-pump coronary artery bypass surgery: comparison between patients with a low and normal pre-graft cardiac index
    Y L Kwak
    Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Research Institute, Yonsei Cardiovascular Research Institute, Yonsei University School of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, South Korea
    Eur J Cardiothorac Surg 26:687-93. 2004
    OBJECTIVE: The effect of pre-emptive milrinone without bolus during off-pump coronary artery bypass surgery (OPCAB) was evaluated in two groups of patients with low and normal pre-graft cardiac index...
  25. ncbi Hemodynamic changes during off-pump coronary artery bypass anastomosis in patients with coexisting mitral regurgitation: improvement with milrinone
    Takeshi Omae
    Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Kagoshima University, Sakuragaoka, Japan
    Anesth Analg 101:2-8, table of contents. 2005
    ..increased in patients with coexisting MR during off-pump coronary artery bypass (OPCAB) anastomosis, and that milrinone could ameliorate increases in MR that occur during OPCAB anastomosis...
  26. ncbi Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery
    Wei Wei
    Providence Heart Institute, Albery Starr Academic Center, Department of Surgery, Oregon Health and Science University, Portland, USA
    J Thorac Cardiovasc Surg 129:33-40. 2005
    ..This study compared the vasopressin-induced contraction and the effects of milrinone, nitroglycerin, and nitroprusside in vasopressin-induced contraction between the human radial artery and the ..
  27. ncbi Inhaled milrinone attenuates experimental acute lung injury
    Moritz Bueltmann
    Department of Anesthesiology, German Heart Institute, Berlin, Germany
    Intensive Care Med 35:171-8. 2009
    To test whether inhalation of the phosphodiesterase 3 inhibitor milrinone may attenuate experimental acute lung injury (ALI).
  28. ncbi Milrinone improves diastolic function in coronary artery bypass surgery as assessed by acoustic quantification and peak filling rate: a prospective randomized study
    Birger Axelsson
    Department of Cardiothoracic Surgery and Anesthesiology, Orebro University Hospital, Orebro, Sweden
    J Cardiothorac Vasc Anesth 24:244-9. 2010
    To compare the effects of a bolus dose of milrinone, 50 microg/kg, to placebo on diastolic function (active relaxation) in patients undergoing on-pump coronary artery bypass grafting (CABG).
  29. ncbi Suppressing apoptosis with milrinone simulating extracorporeal circulation: a pilot study
    E Usta
    Department of Thoracic, Cardiac and Vascular Surgery, Tubingen University Hospital, Tubingen, Germany
    Thorac Cardiovasc Surg 58:285-90. 2010
    ..In addition, the aim was to verify the anti-apoptotic properties of the phosphodiesterase 3 inhibitor milrinone.
  30. ncbi Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery
    R O Feneck
    Department of Anesthesia, St Thomas' Hospital, London, United Kingdom
    J Cardiothorac Vasc Anesth 15:306-15. 2001
    OBJECTIVE: To compare the hemodynamic effects, efficacy, and safety of intravenous milrinone (M), 50 microg/kg during 10 minutes followed by 0...
  31. ncbi Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    Circulation 111:2454-60. 2005
    ..METHODS AND RESULTS: The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study randomized 949 patients with systolic dysfunction ..
  32. ncbi The effect of milrinone on the right ventricular function in patients with reduced right ventricular function undergoing off-pump coronary artery bypass graft surgery
    Jong Hwa Lee
    Department of Anesthesiology and Pain Medicine, College of Medicine, Yonsei University, Seoul, Korea
    J Korean Med Sci 21:854-8. 2006
    This investigation evaluated the effect of continuous milrinone infusion on right ventricular (RV) function during off-pump coronary artery bypass graft (OPCAB) surgery in patients with reduced RV function...
  33. ncbi Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure
    Thomas Hentschel
    Department of Anesthesiology, German Heart Institute Berlin, Institute of Physiology, Charite Universitaetsmedizin Berlin, Campus Benjamin Franklin, Germany
    Anesthesiology 106:124-31. 2007
    ..of a vasodilatory phosphodiesterase-3 inhibitor may reverse this potentially detrimental process, the authors studied the effects of inhaled or intravenous milrinone on pulmonary and systemic hemodynamics in a rat model of CHF.
  34. ncbi Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study
    G Michael Felker
    Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Cardiol 41:997-1003. 2003
    The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF.
  35. ncbi Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease
    Timothy M Hoffman
    Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Circulation 107:996-1002. 2003
    ..This study evaluated the efficacy and safety of prophylactic milrinone in pediatric patients at high risk for developing LCOS...
  36. ncbi Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass
    Christian F Stocker
    Departments of Intensive Care, The Royal Children s Hospital, Melbourne, Australia
    Crit Care Med 35:252-9. 2007
    ..The objectives of our study were to define the early precipitants of the reduced cardiac output and to investigate the effects on these of milrinone and levosimendan in a model of pediatric cardiopulmonary bypass.
  37. ncbi Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs
    Javier Gelvez
    Division of Critical Care Medicine, Miami Children's Hospital, 3100 SW 62nd Avenue, Miami, FL 33156-3009, USA
    Pharmacol Res 50:87-91. 2004
    We tested whether aerosolized milrinone in lambs selectively reduces drug-induced acute pulmonary hypertension without reducing the mean systemic blood pressure (MSBP)...
  38. ncbi Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn
    Patrick J McNamara
    Division of Neonatology, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8
    J Crit Care 21:217-22. 2006
    ..b>Milrinone is a promising adjunctive therapy because of its pulmonary vasodilator properties and cardiotropic effects.
  39. ncbi Predictors of inotrope use during separation from cardiopulmonary bypass
    Kenneth H McKinlay
    Division of Cardiothoracic Anesthesiology and Critical Care, Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
    J Cardiothorac Vasc Anesth 18:404-8. 2004
    ..was defined as the use of dopamine >/=5 microg/kg/min; any dose of epinephrine, norepinephrine, dobutamine, and milrinone; or the insertion of an IABP during separation from CPB...
  40. ncbi Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates
    Armin Sablotzki
    Clinic of Anesthesiology and Intensive Care Medicine, Martin Luther University of Halle Wittenberg, Halle, Germany
    Can J Anaesth 52:1076-82. 2005
    ..A pilot study was under-taken to test the hypothesis that inhaled aerosolized milrinone may cause selective pulmonary vasodilation.
  41. ncbi Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion
    Peter Cheung
    Division of Endocrinology/Diabetes/Metabolism, Clinical Research Center, Temple University School of Medicine, Philadelphia, PA 19141, USA
    Metabolism 52:1496-500. 2003
    In vivo effects of milrinone, a selective phosphodiesterase 3 (PDE-3) inhibitor, on plasma free fatty acids (FFA), glucose, and insulin levels were examined in alert rats...
  42. ncbi Haemodynamic effects of a milrinone infusion without a bolus in patients undergoing off-pump coronary artery bypass graft surgery
    Y L Kwak
    Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute, Yonsei University School of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
    Anaesthesia 59:324-31. 2004
    The haemodynamic effects of a continuous infusion of milrinone without an initial bolus dose were evaluated in patients undergoing off-pump coronary artery bypass graft surgery. After internal mammary artery harvest, milrinone 0.5 microg...
  43. ncbi Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support
    Michel White
    Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada, H1T 1C8
    Clin Sci (Lond) 110:483-9. 2006
    ..C-reactive protein) were measured by ELISA and colorimetric assays at admission and 30 days following 72-h milrinone (n=15) or dobutamine (n=14) infusion...
  44. ncbi A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery
    James M Bailey
    Emory University School of Medicine, Atlanta, GA, USA
    J Pharmacokinet Pharmacodyn 31:43-59. 2004
    The purpose of this study was to ascertain the optimal pharmacokinetic model for milrinone in pediatric patients after cardiac surgery when milrinone was administered as a slow loading dose followed by a constant-rate infusion...
  45. ncbi Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs
    Lothar A Schwarte
    Department of Anesthesiology, , Germany
    Crit Care Med 33:135-42; discussion 246-7. 2005
    ..We compared systemic and regional effects of levosimendan with those of established inotropes, milrinone and dobutamine. DESIGN: Laboratory experiment...
  46. ncbi Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass
    Y Lamarche
    Research Center, and Department of Surgery, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec H1T 1C8, Canada
    J Thorac Cardiovasc Surg 130:83-92. 2005
    ..b>Milrinone is a type III phosphodiesterase inhibitor...
  47. ncbi Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients
    Yunseok Jeon
    Department of Anesthesiology, Seoul National University Hospital, Seoul, Republic of Korea
    Eur J Cardiothorac Surg 29:952-6. 2006
    ..We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine...
  48. ncbi Population pharmacokinetics and dosing regimen design of milrinone in preterm infants
    Mary Paradisis
    Department of Newborn Care, RPA Women and Babies Hospital, Camperdown, NSW, Australia
    Arch Dis Child Fetal Neonatal Ed 92:F204-9. 2007
    To define the pharmacokinetics of milrinone in very preterm infants and determine an optimal dose regimen to prevent low systemic blood flow in the first 12 h after birth.
  49. ncbi Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension
    Ilhan Oztekin
    Anesthesiology Department, Siyami Ersek Thoracic and Cardiovascular Surgery Hospital, Haydarpasa, Istanbul, Turkey
    Yakugaku Zasshi 127:375-83. 2007
    The phosphodiesterase inhibitor milrinone is usually preferred in patients with pulmonary hypertension and myocardial dysfunction after cardiopulmonary bypass...
  50. ncbi Comparison of milrinone versus nitroglycerin, alone and in combination, on grafted internal mammary artery flow after cardiopulmonary bypass: effects of alpha-adrenergic stimulation
    E B Lobato
    Department of Anesthesiology, University of Florida College of Medicine, PO Box 100254, Gainesville, FL 32610 0254, USA
    J Cardiothorac Vasc Anesth 15:723-7. 2001
    To compare changes in blood flow in a grafted internal mammary artery (IMA) after cardiopulmonary bypass (CPB) in response to the administration of milrinone or nitroglycerin and to establish the effects of alpha-adrenergic stimulation.
  51. ncbi The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting
    Mutsuhito Kikura
    Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Anesth Analg 94:22-30, table of contents. 2002
    ..We hypothesized that milrinone or amrinone may reduce their occurrence and catecholamine requirements and increase cellular enzyme levels in ..
  52. ncbi The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting
    Matthias Heringlake
    Department of Anesthesiology, Universitat zu Lubeck, D 23538 Lubeck, Germany
    Crit Care 11:R51. 2007
    ..This prospective, randomized pilot study analyzes the metabolic and renal effects of the inotropes adrenaline and milrinone in patients needing inotropic support after coronary artery bypass grafting (CABG).
  53. ncbi Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases
    Y Arakawa
    Department of Neurosurgery, Kurashiki Central Hospital, Okayama, Japan
    Neurosurgery 48:723-8; discussion 728-30. 2001
    ..b>Milrinone is an inotropic drug that dilates vessels by phosphodiesterase inhibition in a mechanism similar to that of ..
  54. ncbi Nebulized milrinone use in a pulmonary hypertensive crisis
    Mitchell S Buckley
    Department of Pharmacy, St Joseph s Hospital and Medical Center, Phoenix, Arizona, USA
    Pharmacotherapy 27:1763-6. 2007
    ..b>Milrinone, a phosphodiesterase inhibitor, remains a therapeutic option...
  55. ncbi Effects of milrinone for right ventricular failure after left ventricular assist device implantation
    Shin ichiro Kihara
    Department of Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women s Medical University
    Heart Vessels 16:69-71. 2002
    ..with right ventricular failure after left ventricular assist device implantation successfully treated with milrinone. Both had residual pulmonary hypertension due to high pulmonary vascular resistance after left ventricular ..
  56. ncbi Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression
    Christian A Schmittinger
    Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
    Crit Care 12:R99. 2008
    ..The multifactorial etiology of septic cardiomyopathy is not fully elucidated. Recently, high catecholamine levels have been suggested to contribute to impaired myocardial function...
  57. ncbi Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB)
    T Mollhoff
    Klinik und Poliklinik für Anästhesiologie und operative Intensivmedizin, Westfälische Westfälische Wilhelms Universität Münster, Germany
    Anesthesiology 90:72-80. 1999
    ..The authors evaluated the effects of milrinone on splanchnic oxygenation, systemic inflammation, and the subsequent acute-phase response in patients undergoing ..
  58. ncbi A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery
    J P Rathmell
    Department of Anesthesiology, University of Vermont College of Medicine, Burlington 05401, USA
    Anesth Analg 86:683-90. 1998
    Amrinone and milrinone are phosphodiesterase inhibitors with positive inotropic effects useful for the treatment of ventricular dysfunction after cardiac surgery...
  59. ncbi Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A
    C J Smith
    Department of Pathology, New York Medical College, Valhalla 10595, USA
    Circulation 96:3116-23. 1997
    ..Little is known about relative changes in PDE3 activity or gene expression during the evolution of cardiomyopathy...
  60. ncbi Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation
    Kyota Fukazawa
    Division of Solid Organ Transplantation, Department of Anesthesiology, Preoperative Medicine and Pain Management, University of Miami Leonard M Miller School of Medicine, Miami, FL 33136, USA
    Clin Transplant 24:515-9. 2010
    ..We quickly determined the reversibility of PPHN with a bolus of milrinone and proceeded with OLT...
  61. ncbi Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure
    Eiran Z Gorodeski
    Section of Heart Failure and Cardiac Transplant Medicine, Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Circ Heart Fail 2:320-4. 2009
    There are no published clinical trials comparing dobutamine with milrinone in outpatients with stage D heart failure on continuous inotropes.
  62. ncbi Preliminary experience with inhaled milrinone in cardiac surgery
    Yoan Lamarche
    Research Center, Montreal Heart Institute and Universite de Montreal, 5000 Belanger Street, Montreal, Quebec H, Canada
    Eur J Cardiothorac Surg 31:1081-7. 2007
    Inhaled administration of milrinone reduces pulmonary artery pressure. Pulmonary hypertension (PH) and right heart failure are associated with difficult separation from cardiopulmonary bypass (CPB)...
  63. ncbi Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery
    Hongmei Wang
    Department of Anesthesiology, Second Affiliated Hospital, Zhejiang University, Hangzhou, China
    Adv Ther 26:462-8. 2009
    ..The aim of this study was to investigate the postoperative hemodynamic effects of milrinone inhalation, and determine whether it has a selective effect of pulmonary vasodilation in patients with pulmonary ..
  64. ncbi The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension
    A Haraldsson s
    Department of Anesthesia and Intensive Care, Sahlgrenska University Hospital, , Sweden
    Anesth Analg 93:1439-45, table of contents. 2001
    ..We hypothesized that milrinone, an adenosine-3',5'-cyclic monophosphate (cAMP)-selective phosphodiesterase enzyme (PDE) inhibitor may, when ..
  65. ncbi Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial
    Michael S Cuffe
    Northwestern University Medical School, Division of Cardiology, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
    JAMA 287:1541-7. 2002
    ..Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain...
  66. ncbi Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol
    B D Lowes
    University of Colorado Health Sciences Center, Denver, Colorado, CO 80262, USA
    Int J Cardiol 81:141-9. 2001
    To compare the efficacy of milrinone and dobutamine in patients chronically treated with carvedilol.
  67. ncbi Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries
    G W He
    Albert Starr Academic Center for Cardiac Surgery, St Vincent Hospital and Medical Center, Portland, Oregon, USA
    Br J Clin Pharmacol 41:101-7. 1996
    ..The purpose of this study was to test the hypothesis that the phosphodiesterase III inhibitor milrinone and nitroglycerin (NTG) may have greater than additive effects in human arteries. 2...
  68. ncbi Effects of milrinone and butyrolactone-I on porcine oocyte meiotic progression and developmental competence
    Christopher G Grupen
    Research Centre for Reproductive Health, Department of Obstetrics and Gynaecology, The University of Adelaide, The Queen Elizabeth Hospital, Woodville Road, Woodville, SA 5011, Australia
    Reprod Fertil Dev 18:309-17. 2006
    ..With the aim of improving this coordination, the effects of milrinone, an inhibitor of type 3 phosphodiesterases, and butyrolactone-I, a selective inhibitor of cdc2 kinases, on ..
  69. ncbi Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart
    Petri Kaheinen
    Orion Pharma, Espoo, Finland
    J Cardiovasc Pharmacol 43:555-61. 2004
    ..a novel calcium sensitizer that increases contraction force without change in intracellular calcium ([Ca2+]i); milrinone is a phosphodiesterase inhibitor that exerts a positive inotropic effect by increasing [Ca2+]i...
  70. ncbi Dose-response effects of milrinone on hemodynamics of newborn pigs with hypoxia-reoxygenation
    Chloe Joynt
    Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
    Intensive Care Med 34:1321-9. 2008
    Neonatal asphyxia causes cardiogenic shock and pulmonary hypertension with decreased brain perfusion. We examined the dose-response of milrinone on systemic, pulmonary, and carotid circulations in a model of neonatal hypoxia-reoxygenation.
  71. ncbi Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension
    Felipe Urdaneta
    Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida 32610-0254, USA
    Ann Thorac Surg 78:1433-7. 2004
    ..The phosphodiesterase enzyme type III inhibitor milrinone produces pulmonary vasodilation but lacks selectivity...
  72. ncbi Milrinone increases middle cerebral artery blood flow velocity after cardiopulmonary bypass
    Cheri A Sulek
    Department of Anesthesiology, University of Florida College of Medicine, and Veterans Affairs Medical Center, Gainesville, FL 32610, USA
    J Cardiothorac Vasc Anesth 16:64-9. 2002
    To evaluate the effects of milrinone on middle cerebral artery blood flow velocity (Vmca) and pulsatility index (PI) during normocapnia and hyperventilation in adults after cardiopulmonary bypass (CPB).
  73. ncbi Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs
    Avner Sidi
    Department of Anesthesiology, University of Florida College of Medicine and Anesthesia Service, Malcom Randall Veterans Administration Medical Center, Gainesville, Florida, USA
    Ann Card Anaesth 10:34-41. 2007
    This study examined milrinone effects on ischaemic myocardial metabolism and function with calcium blockade...
  74. ncbi Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy
    Geetha Bhat
    Heart Failure and Cardiac Transplant Center, Jewish Hospital, Louisville, Kentucky, USA
    ASAIO J 52:677-81. 2006
    Home-based milrinone therapy (HMT) is used as a bridge to cardiac transplant (CT). The safety, efficacy, and predictors of success of HMT were assessed. Forty-five patients with heart failure, referred for CT, were prospectively studied...
  75. ncbi Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine
    Tadasuke Use
    Department of Anesthesiology, Nagasaki University School of Medicine, 1 7 1 Sakamoto, Nagasaki, Japan
    Cardiovasc Drugs Ther 20:327-34. 2006
    We assessed the dose or timing effect of milrinone administered against myocardial stunning in 37 anesthetized open-chest swine.
  76. ncbi Chronic inotropic therapy in end-stage heart failure
    Paul J Hauptman
    Division of Cardiology, Department of Medicine, Saint Louis University School of Medicine, St Louis, MO, USA
    Am Heart J 152:1096.e1-8. 2006
    ..However, little is known about associated mortality and cost. Therefore, we sought to describe the impact of chronic infusions on resource use and survival...
  77. ncbi Home inotropic therapy in children
    Alexandria M Berg
    Sibley Heart Transplant Center, Children s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Heart Lung Transplant 26:453-7. 2007
    ..In adults, home inotropic therapy has been shown to be a safe and cost-effective bridge to transplantation. To date, there are limited data on the use of home inotropic therapy in children...
  78. ncbi Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide
    Shaun Kurien
    Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Cardiol 98:1627-30. 2006
    ....
  79. ncbi Impaired vasoreactivity in end-stage heart failure patients on intravenous inotropic support
    Abigail S Dean
    Cardiovascular Research Center, Temple University, Philadelphia, Pennsylvania, USA
    J Card Fail 11:351-7. 2005
    ..1% versus ES-HF; -5.3 +/- 1.5%, P < .05). CONCLUSION: Peripheral vasoreactivity in response to either maximal exercise, submaximal exercise, or hyperemic stimuli is impaired in ES-HF patients with normal resting cardiac outputs...
  80. ncbi Cardiovascular pharmacotherapy update for the intensive care unit
    James C Coons
    Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Crit Care Nurs Q 30:44-57. 2007
    ..We also highlight innovations in pharmacotherapy for this patient population, and provide practical considerations for the most appropriate and safe use of these medications...
  81. ncbi Levosimendan and gut mucosal blood flow--not all inotropes are created equal
    Craig M Coopersmith
    Crit Care Med 33:246-7. 2005
  82. ncbi The effects of levosimendan in cardiac surgery patients with poor left ventricular function
    Stefan G De Hert
    Department of Anesthesiology, University of Antwerp, University Hospital Antwerp, Belgium
    Anesth Analg 104:766-73. 2007
    ....
  83. ncbi [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects]
    Naoki Sato
    Intensive and Cardiac Care Unit, Nippon Medical School
    Nippon Rinsho 65:43-8. 2007
  84. ncbi Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
    Paul S Pagel
    Anesth Analg 104:759-61. 2007
  85. ncbi A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts
    York A Zausig
    Department of Anaesthesia, ZARI, University of Goettingen, Goettingen, Germany
    Anesth Analg 102:1646-52. 2006
    ..We found that, over a range from 10(-7) to 10(-4) M, amrinone, enoximone, and milrinone each produced maximal concentration-dependent positive chronotropic (12%, 18%, 26%), inotropic (16%, 26%, 26%), ..
  86. ncbi Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
    Vladislava Simkova
    Sektion Anasthesiologische Pathophysiologie und Verfahrensentwicklung, Universitatsklinikum, Parkstrasse 11, D 89073 Ulm, Germany
    Crit Care 11:139. 2007
    ..Their effects on energy metabolism and visceral organ function are not well studied, however, particularly in comparison with their 'competitors' in daily practice (that is, catecholamines)...
  87. ncbi Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure
    Bengt Herweg
    Division of Cardiology, Tampa General Hospital, University of South Florida College of Medicine, Tampa, Florida, USA
    Am J Cardiol 100:90-3. 2007
    ..Intravenous inotropic therapy consisted of dobutamine (n = 6; 4.3 +/- 1.9 microg/kg/min) or milrinone (n = 4; 0.54 +/- 0...
  88. ncbi Effects of milrinone on blood flow of the Y-graft composed with the radial and the internal thoracic artery in patients with coronary artery disease
    Sungwon Na
    Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-ku, Seoul 120-725, South Korea
    Eur J Cardiothorac Surg 30:324-8. 2006
    OBJECTIVE: Milrinone has been known to dilate the internal thoracic artery (ITA) and the radial artery (RA). The effect of milrinone, however, on each graft is unclear when the left ITA (LITA) and the RA form a Y-graft...
  89. ncbi Optimizing outcomes in the patient with acute decompensated heart failure
    Mandeep R Mehra
    Division of Cardiology, Department of Medicine, University of Maryland, Baltimore, MD, USA
    Am Heart J 151:571-9. 2006
    ....
  90. ncbi Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
    Patricia N Banfor
    Department of Integrative Pharmacology R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6119, USA
    Am J Physiol Heart Circ Physiol 294:H238-48. 2008
    ..Results were compared with those of the beta(1)-agonist dobutamine and the phosphodiesterase 3 inhibitor milrinone. Peak concentrations of levosimendan, OR-1896, and OR-1855 were 455 +/- 21, 126 +/- 6, and 136 +/- 6 ng/ml, ..
  91. ncbi Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure
    Naoki Sato
    Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan
    Clin Cardiol 29:263-7. 2006
    ..However, whether arterial baroreflex function is related to the inotropic responsiveness to a PDEI has not been clarified in human heart failure (HF)...
  92. ncbi Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure
    Lindsay M Arnold
    Department of Pharmacy, Boston Medical Center, Boston, Massachusetts, USA
    Pharmacotherapy 26:1078-85. 2006
    ..of acute decompensated heart failure (ADHF) in patients receiving intravenous treatment with dobutamine, milrinone, or nesiritide, and to evaluate differences, based on treatment received, in the in-hospital mortality rate, ..
  93. ncbi Treatment of ischaemic left ventricular dysfunction with milrinone or dobutamine administered during coronary artery stenosis in the presence of beta blockade in pigs
    A Sidi
    Department of Anesthesiology, University of Florida, College of Medicine, Gainesville, FL, USA
    Br J Anaesth 97:799-807. 2006
    ..This study examines the effects of phosphodiesterase type III (PDEIII) inhibition vs beta stimulation on global function of the left ventricle (LV) and systemic haemodynamics in a porcine model of acute coronary stenosis with beta blockade...
  94. ncbi Classical inotropes and new cardiac enhancers
    John T Parissis
    Heart Failure Unit, Attikon University Hospital, Athens, Greece
    Heart Fail Rev 12:149-56. 2007
    ..Classical inotropes, such as beta-agonists (dobutamine, dopamine) and phosphodiesterase inhibitors (milrinone), seem to improve clinical symptoms and hemodynamics of acutely decompensated chronic heat failure patients, but ..
  95. ncbi Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes
    Melike Bayram
    Department of Medicine Residency Training Program, University of Michigan, Ann Arbor, Michigan, USA
    Am J Cardiol 96:47G-58G. 2005
    ..on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS...
  96. ncbi Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure
    Qihang Zhang
    Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, One Robert Wood Johnson Place, CN-19, New Brunswick, NJ 08903-0019, USA
    Am J Physiol Heart Circ Physiol 289:H1251-7. 2005
    ..erythro-9-(2-hydroxy-3-nonyl)adenine [EHNA; a cAMP phosphodiesterase (PDE(2)) inhibitor] plus 8-bromo-cGMP, or milrinone (a PDE(3) inhibitor) plus 8-bromo-cGMP...
  97. ncbi Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes
    Jonas Jurevicius
    , INSERM U-446, , , , France
    J Physiol 551:239-52. 2003
    ..While PDE1 and PDE2 inhibition had no effect, PDE3 inhibition by milrinone (3 microM) or PDE4 inhibition by Ro 20-1724 (3 microM) reduced alpha by 6- and 4-fold, respectively...
  98. ncbi Critical care in cardiovascular medicine
    Chitra Ravishankar
    Department of Pediatrics, Children s Hospital of Philadelphia, Pennsylvania, USA
    Curr Opin Pediatr 15:443-53. 2003
    ..The authors also briefly review the recent advances in the treatment of pulmonary hypertension, mechanical support, and neurologic surveillance after cardiac surgery...
  99. ncbi Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controled pilot study
    Angel Lopez-Candales
    Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    J Med 33:129-46. 2002
    ..6 +/- 0.5) met all the inclusion and none of the exclusion criteria to receive intravenous milrinone, dobutamine, or matching placebo...
  100. ncbi Milrinone
    Susan Givens Bell
    NICU, All Children's Hospital, St. Petersburg, Florida, USA
    Neonatal Netw 22:61-3. 2003
  101. ncbi The evolving management of acute right-sided heart failure in cardiac transplant recipients
    B Stobierska-Dzierzek
    Division of Cardiothoracic Surgery, Ohio State University, Columbus, Ohio 43201-1214, USA
    J Am Coll Cardiol 38:923-31. 2001
    ..Only through careful preoperative planning can this life-threatening condition be managed in the postoperative period...

Research Grants101 found, 100 shown here

  1. MYOCARDIAL ENERGY METABOLISM IN THE DYSFUNCTIONAL LV
    Jianyi Zhang; Fiscal Year: 2003
    ..be produced by direct stimulation of adenylyl cyclase with forskolin or by inhibition of phosphodiesterase with milrinone in addition to catecholamine infusion...
  2. EFFECTS OF HORMONES ON BONE RESORPTION IN VITRO
    Paula Stern; Fiscal Year: 1992
    ..g. tamoxifen, cyclosporine, and milrinone) will be tested for their effects on the Ca/phosphatidylinositol pathway...
  3. Potentiation of Ang II-Induced Renal Vasoconstriction
    Edwin Jackson; Fiscal Year: 2006
    ....
  4. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
    ..These studies will form the conceptual framework for an intervention study designed to address, at physician and patient levels, the process of selection of care options for older heart failure patients near the end of life. ..
  5. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2007
    ....
  6. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2009
    ....
  7. Potentiation of Ang II Induced Renal Vasoconstriction
    Edwin Jackson; Fiscal Year: 2007
    ..The testing of this hypothesis is the focus of this application. The proposed hypothesis is absolutely novel. The concept that DPP IV exists in the renal vasculature and regulates renal blood flow has never been proposed or tested. ..
  8. Regulation of Renal Cortical Adenosine Levels
    Edwin K Jackson; Fiscal Year: 2010
    ..It is conceivable that this project will provide information leading to safer and more effective drug-eluting stents. ..
  9. Potentiation of Ang II Induced Renal Vasoconstriction
    Edwin K Jackson; Fiscal Year: 2010
    ..The testing of this hypothesis is the focus of this application. The proposed hypothesis is absolutely novel. The concept that DPP IV exists in the renal vasculature and regulates renal blood flow has never been proposed or tested. ..
  10. Regulation of Renal Cortical Adenosine Levels
    Edwin Jackson; Fiscal Year: 2009
    ..It is conceivable that this project will provide information leading to safer and more effective drug-eluting stents. ..
  11. CYCLIC AMP/ADENOSINE PATHWAY
    Edwin Jackson; Fiscal Year: 2002
    ..abstract_text> ..
  12. PKC-EHN-PKD signal complex in cardiac remodeling
    Masahiko Hoshijima; Fiscal Year: 2009
    ..abstract_text> ..
  13. Regulation of Mammalian Oocyte Maturation
    Stephen Downs; Fiscal Year: 2007
    ..Furthermore, these studies will benefit the development of in vitro systems where either meiotic arrest or completion of meiotic maturation is the desired endpoint. ..
  14. REGULATION OF CGMP DEPENDENT PROTEIN KINASE
    Jackie Corbin; Fiscal Year: 2002
    ..Physiological regulation of PKG protein and mRNA levels will be explored. Results of these investigations will address major aspects of cGMP signaling through PKG. ..
  15. Improving Drug Development for the Critically Ill Child
    Athena Zuppa; Fiscal Year: 2007
    ..This intensive didactic and mentored training will allow for the development of a future independent pediatric clinical investigator. ..
  16. Ischemic Arrest, Cytokines, and Organ Dysfunction
    James Niemann; Fiscal Year: 2007
    ..In aim 3, the effect of anti-TNF therapy on long-term survival and neurologic outcome will be evaluated. ..
  17. Impact of Pharmacology on Duration of Ventilation in Patients with Resp Failure
    Athena F Zuppa; Fiscal Year: 2010
    ....
  18. Vascular tone & cAMP phosphodiesterase in angioplasty
    Carolyn Smith; Fiscal Year: 2002
    ..Upregulation of specific PDEs represents an important response to injury that may serve as a therapeutic target in restenosis and hypertension ..
  19. Olfactory Circuits for Reproduction and Reward
    James A Cherry; Fiscal Year: 2010
    ..We propose to study this pathway in the mouse to determine how odors may be involved in regulating mate choice, sexual motivation and reward. ..
  20. ACTION-A CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE
    William Abraham; Fiscal Year: 2005
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  21. Renin regulation by nitric oxide
    WILLIAM BEIERWALTES; Fiscal Year: 2007
    ..These studies should reveal the dual pathways by which NO can either inhibit or stimulate renin secretion. ..
  22. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  23. University of Montreal Cardiac Surgery Clinical Investigation Group
    LOUIS PERRAULT; Fiscal Year: 2007
    ..End of Abstract) ..
  24. SEXUAL DIFFERENTIATION OF MOUSE VOMERONASAL FUNCTION
    James Cherry; Fiscal Year: 2004
    ....
  25. Olfactory Circuits for Reproduction and Reward
    James A Cherry; Fiscal Year: 2011
    ..We propose to study this pathway in the mouse to determine how odors may be involved in regulating mate choice, sexual motivation and reward. ..